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Abstract
Background: Most individuals who died of trauma were found to harbour microscopic primary cancers at autopsies. 
Surgical excision of the primary tumour, unfortunately, seems to disturb tumour dormancy in over half of all metastatic 
relapses.
Presentation of the hypothesis: A recently developed immune model suggested that the evolutionary pressure 
driving the creation of a T cell receptor repertoire was primarily the homeostatic surveillance of the genome. The 
model is based on the homeostatic role of T cells, suggesting that molecular complementarity between the positively 
selected T cell receptors and the self peptide-presenting major histocompatibility complex molecules establishes and 
regulates homeostasis, strictly limiting variations of its components. The repertoire is maintained by continuous 
peripheral stimulation via soluble forms of self-peptide-presenting major histocompatibility complex molecules 
governed by the law of mass action. The model states that foreign peptides inhibit the complementary interactions 
between the major histocompatibility complexes and T cell receptors. Since the vast majority of clinically detected 
cancers present self-peptides the model assumes that tumour cells are, paradoxically, under homeostatic T cell control.
The novelty of our hypothesis therefore is that resection of the primary tumour mass is perceived as loss of 'normal' 
tissue cells. Consequently, T cells striving to reconstitute homeostasis stimulate rather than inhibit the growth of 
dormant tumour cells and avascular micrometastases. Here we suggest that such kick-start growths could be 
prevented by a recombinant T cell receptor ligand therapy that modifies T cell behaviour through a partial activation 
mechanism.
Testing the hypothesis: The homeostatic T cell regulation of tumours can be tested in a tri-transgenic mice model 
engineered to express potent oncogenes in a doxycycline-dependent manner. We suggest seeding dissociated, 
untransformed mammary cells from doxycycline naïve mice into the lungs of two mice groups: one carries mammary 
tumours, the other does not. Both recipient groups to be fed doxycycline in order to activate the oncogenes of the 
untransformed mammary cells in the lungs, where solitary nodules are expected to develop 6 weeks after injection. We 
expect that lung metastasis development will be stimulated following resection of the primary tumour mass 
compared to the tumour-free mice. A recombinant T cell receptor ligand therapy, starting at least one day before 
resection and continuing during the entire experimental period, would be able to prevent the stimulating effect of 
surgery.
Implications of the hypothesis: Recombinant T cell receptor ligand therapy of diagnosed cancer would keep all 
metastatic deposits microscopic for as long as the therapy is continued without limit and could be pursued as one 
method of cancer control. Improving the outcome of therapy by preventing the development of metastases is perhaps 
achievable more readily than curing patients with overt metastases.
Background
Two out of three humans never develop cancer [1]. Nev-
ertheless, most individuals, with no apparent pathology,
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but who died of trauma, were found to harbour micro-
scopic primary cancers revealed at autopsies [2]. This
phenomenon is related to the so-called tumour dor-
mancy, a reference to latent cancer cells. It has been
defined as 'the disease free period' between clinical 'cure'
of the primary cancer and its subsequent local or distant
recurrence/metastasis. Tumour dormancy is a reversible
process [3].
Breast cancer, for example, may recur as long as 50
years after surgery [4]. One third of patients, 7 to 22 years
after mastectomy and without any evidence of disease,
had circulating tumour cells (CTCs). Since the half-life of
these CTCs is probably 1 to 3 hours, a precise balance
between replication of tumour cells and cell death seems
very likely. It has been suggested that the dying CTCs
require getting replenished every few hours by replicating
tumour cells somewhere in the tissues [5]. Presumably, in
a major population of clinically cured patients, 'dormant'
breast cancer may be thought of as a chronic disease,
which is kept in check by the patients' own physiological
mechanisms [6].
Such findings may be explained by the so-called tumour
homeostasis paradigm [7], which considers tumours as an
organ-like structure assuming a dynamic and reciprocal
relationship between genetically damaged cells and their
microenvironment. The original seed and soil hypothesis
[8] was refined recognizing that metastases of solid
tumours require collaborative interactions between
malignant cells and a diverse assortment of "activated"
stromal cells at both primary and secondary tumour loca-
tions [9].
In the above context, century old observations that sur-
gery of malignant tumours may be the reason for
enhancement of growth of metastases with fatal outcome
perhaps make sense [7,10-12]. In fact, such experiences
often prevented surgeons from touching the tumour if it
was not absolutely necessary. Particularly, data in four-
teen separate databases from different countries indi-
cated the existence of two peaks in relapse frequency for
distal plus local relapses among early stage breast cancer
patients, who were untreated with adjuvant therapy (see
for references in [12]). As suggested earlier [13], this com-
plex relapse pattern cannot be explained simply by unre-
strained continuous cellular growth. Rather the dominant
mode of relapse in early-stage breast cancer could be the
iatrogenic interference with and most unfortunately ter-
minating dormancy at the time of surgery, precipitating
accelerated relapses [14]. In fact, over half of all meta-
static relapses seem to be induced by such iatrogenic
events [12]. Paradoxically, it has also been shown that a
primary tumour may inhibit the growth of metastases in
the liver [15].
Compounding the above problem that despite com-
plete resection of the tumour with tumour free margins
in all patients, during the following 3 to 4 days, in 85% of
treated patients epithelial cells started increasing up to a
thousand fold. After resection of tumours, even if they
are small and resection is complete, cells can remain in
the circulation over long periods of time [16].
Since dormant tumour cells are highly refractory to
chemotherapy, leading to uncertainty in the prognosis for
patients already treated for primary cancer, a NIH work-
shop envisioned tumour dormancy as a therapeutic end-
point [17]. Such an objective however requires chronic
therapy.
Importantly, the surgical reactivation of metastasis is
just one of many other possible theories explaining sur-
gery-induced immune suppression, which increases with
larger incisions [18]. In fact, concerns of tumour dissemi-
nation related to tumour manipulation led to the explo-
sion of the minimally invasive surgery in the 1990s.
Almost every procedure traditionally performed via lapa-
rotomy has been performed successfully by laparoscopic
methods, including pancreaticoduodenectomy for cancer
[19].
Presentation of the hypothesis
If the majority of humans harbour microscopic cancer
and the switch of these tumours to the angiogenic pheno-
type is so infrequent, then this " Achilles' heel" of cancer
progression could be exploited to prevent the growth of
many harmless early lesions to the few lethal tumours,
currently detectable and treatable [20]. In fact, recently in
this journal, Retsky et al. [21] suggested such a therapy for
early stage breast cancer. To prevent micrometastatic
angiogenesis resulting from surgery or at any time later,
they suggest employing the primary antiangiogenic
Endostatin starting at least one day before surgery and
continuing indefinitely since no acquired resistance
develops.
Persistent pro-tumour immune responses (inflamma-
tion), now generally accepted as potentiating primary
tumour development, are being recognized as mediators
of cancer metastasis [22]. Therefore, inhibition of metas-
tases at secondary sites by fostering maintenance of
immune and tissue homeostasis offers promising
approach for cancer therapy when dormant malignant
disease might be suspected to occur. In order to prevent
the kick-start growth of micrometastases by surgical
resection of the primary tumour, we propose a predict-
ably feasible new 'physiological' therapy approach, which
is based on the homeostatic role of T cells model [23]. We
believe that crucially the virtue of our hypothesis is that
the evolutionary pressure driving the creation of a T cell
receptor (TCR) repertoire was primarily the homeostatic
surveillance of the genome. The TCR repertoire appears
to provide a complementary image of the host proteins
expressed such that it facilitates the formation of aBakács and Mehrishi BMC Cancer 2010, 10:251
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homeostatic coupled system that restricts variation of T
cells and host cells. The TCR repertoire is maintained by
continuous peripheral stimulation via soluble forms of
self-peptide-presenting major histocompatibility com-
plex (MHC) molecules governed by the law of mass
action [24] [see Fig. 1, Fig.2 and video clip in additional
file 1 and also in [23,25].
The homeostatic T cell model states that only foreign
peptides inhibit the complementary TCR-MHC interac-
tions. Since the vast majority of clinically detected can-
cers present self-peptides - because they lack tumour
associated antigens - the homeostatic T cell model
assumes that tumour cells are, paradoxically, controlled
by homeostatic T cells. The novelty of our hypothesis
therefore is that resection of the primary tumour mass is
perceived as loss of 'normal' tissue cells. Consequently, T
cells striving to reconstitute homeostasis stimulate rather
than inhibit the growth of dormant tumour cells and
avascular micrometastases. An example that may
enlighten our hypothesis is liver resection for metastatic
(colorectal carcinoma) tumours, often followed by a sig-
nificant incidence of tumour recurrence. This might indi-
cate that factors involved in liver regeneration may also
stimulate the growth of 'sleeping' tumours and the reacti-
vation of dormant micrometastases [26].
We suggest therefore that such homeostatic T cell stim-
ulation could be prevented by a recombinant TCR ligand
("RTL"), which is composed of a naturally processed pep-
tide product from normal mammary cells covalently
ligated to a major histocompatibility complex class I mol-
ecule. Appropriate normal (non-tumour-type-specific)
peptides may be identified by genomic and proteomic
methodologies using cell-displayed peptide libraries car-
rying intrinsic fluorescent marker allowing for sorting
and characterization with quantitative flow cytometry
[27].
RTLs - the peptide binding/T cell recognition domains
of MHC class II molecules - have emerged as a new class
of therapeutic agents with potent clinical efficacy in a
diverse set of animal models for multiple sclerosis [28].
The RTL molecule consists of the peptide-binding
beta1alpha1 domain of MHC class II covalently ligated to
a peptide separating it from the alpha2beta2 domain that
may provide additional signalling through CD4 or other
cell surface molecules. RTL can bind directly to the TCR
and present native antigenic peptides in the context of
MHC - i.e. an optimal signal 1 - without costimulation
f r o m  a n t i g e n  p r e s e n t i n g  c e l l s  ( A P C s ) .  T h i s  w a y ,  R T L
modifies T cell behaviour through a partial activation
mechanism that accounts for the inhibitory effects of
RTL on encephalitogenic CD4+ T cells. Here we suggest
that an RTL therapy would be able to inhibit the homeo-
static T cell stimulation of disseminated tumour cells
(after resection of the primary tumour) through a partial
activation mechanism. It would prolong the natural ten-
dency for dormancy in the early stages of the disease,
keep all metastatic deposits microscopic for as long as the
therapy would continue without limit and could be pur-
sued as one method of cancer control. Breast cancer is
the most obvious target, but this idea could be applied to
other cancers as well.
Clearly, an RTL therapy cannot substitute the antigen
specific immunotherapeutic strategies aimed at activat-
ing the immune system to recognize and destroy tumour
cells (e.g. cancer vaccine to stimulate p53-specific T cells
using autologous dendritic cells pulsed with various
HLA-A*0201 binding wild-type p53 derived peptides
used in HLA-A2+ patients with progressive late-stage
metastatic breast cancer [29]). Rather the two approaches
Figure 1 Strong medicine. The human T cell, a multitasking agent 
in the immune system, is normally activated only when two re-
ceptors are stimulated (left). But the "superagonist" used in a Lon-
don clinical trial can activate T cells by stimulating a single receptor 
(right). Credit: (illustration) C. Bickel/Science. Reproduced with permis-
sion from Marshall E. Drug trials. Violent reaction to monoclonal anti-
body therapy remains a mystery. Science 2006;311(5768):1688-9.
Figure 2 A single frame is presented from the video clip of the 
Homeostatic Role of T cells model. Reproduced with permission of 
S. Karger AG, Basel from Bakacs T, Mehrishi JN, Szabados T, Varga L, Sza-
bo M, Tusnady G. T Cells Survey the Stability of the Self: A Testable Hy-
pothesis on the Homeostatic Role of TCR-MHC Interactions. Int Arch 
Allergy Immunol 2007;144:171-82.
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would probably complement each other. A good place to
start such combined efforts is melanoma, which has long
been recognized to be immunogenic; furthermore, the
clinical facts confirm the metastatic dormancy of mela-
noma. Definitive proof is available that the immunogenic
c h a r a c t e r  o f  t h i s  c a n c e r  i s  a s s o c i a t e d  w i t h  d o r m a n c y .
Melanoma cells persisted in a dormant state in the kidney
of a donor for 16 years and upon transplantation to two
different but immune-suppressed hosts, they emerged
from dormancy [30]. In fact, clinical and experimental
data on melanoma indicate that some aspects of mela-
noma biology imitate traits recently associated with dor-
mancy in other solid cancers [31]. Cutaneous and uveal
melanoma, in spite of being of the same origin, differs
profoundly in their clinical progression. Between 40 and
50% of uveal melanoma remain undetected for longer
than a decade, while less than 5% of cutaneous melanoma
show this behaviour. This difference may also have
immunologic origin. The eye, the site of uveal melanoma,
is rich in immunosuppressive and anti-inflammatory fac-
tors, which dampen both innate and adaptive immune
responses [31].
Testing the hypothesis
The protective effect of RTL therapy on the iatrogenic
effect of primary tumour resection could be tested in a
tri-transgenic mouse model engineered to express potent
oncogenes in a doxycycline-dependent mammary-spe-
cific manner [32]. Such animals develop diffuse autoch-
thonous tumours only after doxycycline exposure within
3 to 4 weeks. Podsypanina et al. [33] demonstrated that in
the absence of oncogene activation untransformed mam-
mary cells are capable of travelling to and surviving in the
lungs for up to 16 weeks, grow slowly and remain clini-
cally undetectable. Such cells, however, may assume
malignant growth upon oncogene activation.
We suggest therefore seeding of dissociated primary
mammary cells from doxycycline naïve mice, via the lat-
eral tail veins, in the lungs of two groups of mice: the first
group unexposed to doxycycline and the second one with
primary mammary tumours developed following doxycy-
cline exposure. Now both recipient mice groups are
administered doxycycline to activate the oncogenes of the
untransformed mammary cells in the lungs, where soli-
tary nodules are expected to develop 6 weeks after injec-
tion [33]. At the start of this feeding animals in both the
groups would undergo a sham resection in the first group
and resection of the primary tumour in the second group.
Based on the prediction of the homeostatic T cell model
we would expect that lung metastasis development will
be faster in animals from which the primary tumour mass
had been removed.
We envisage that an RTL therapy, starting at least one
day before surgery and continuing during the entire
experimental period, would be able to prevent the growth
stimulating effect of surgery.
Implications of the hypothesis
Jørgensen and Gøtzsche [34] recently reported 52% over-
diagnosis of breast cancer in a population offered
organised mammography screening - that is, one in three
breast cancers is over diagnosed. Others [35-37] judged
that screening for cancer, while beneficial, might lead to
over diagnoses and over treatment, thus perhaps it is best
to leave it alone. Sadly, this would mean that 'one in 400
women not screened for any potential treatment for
tumour remaining undiagnosed will die within the next
10 years' [38].
Leaving the choice to patients rather than to highly
experienced professionals in a matter of almost 'life and
death', would place an intolerable burden on those
already distressed and looking for sound decisions. Using
adjuvant RTL therapy, however, one may not have to
choose between the evils of undiscovered primary
tumours in unscreened patients and induction of metas-
tases in treated ones - like Odysseus having to choose
between two life-threatening evils, Scylla and Charybdis,
but managing to avoid both.
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Additional file 1 Video clip. The body is constantly attacked by infections 
and defended by a collection of antibodies. The infections are represented 
by 'lightings' that have colours: light or dark blue and silver. The antibody fil-
ter has the same colours. The circle is the body containing a tube, which is 
the lymphoid vessel. The tissue cells (coloured red, yellow, white, brown 
and purple) are in the central upper part. T cells are located in the lymph 
node at the edge of the lymphoid vessel. A large APC is located in the lower 
part. Tissue cell-derived peptides determine TCR specificity. Colours of T 
cells designate the self pMHCs, which rescued them during positive selec-
tion. Complementary self pMHCs and TCRs have identical colours. For the 
sake of simplicity, in the animation the many different self pMHCs in a sin-
gle cell are neglected. One T cell recognizes only one self pMHC. The ani-
mation shows how the whole system is capable of determining whether a 
given pMHC is self or non-self. An individual T cell is unable to make such a 
decision. Together, however, they can because there is a complementary 
TCR for every self pMHC in the immune system that recognizes an individ-
ual peptide fragment. The self pMHCs are presented, one by one, as they 
flow via the lymph into the lymph node. Eventually, all soluble self pMHCs 
are captured by complementary TCRs. In this way all tissue cells remain 
intact. Finally, a viral infection, designated by green colour, enters the body 
and infects a cell changing its self peptide into a foreign peptide (fpMHC). 
The soluble f pMHC molecule (the danger signal in the Homeostatic Role of 
T cells model) freely crosses the lymphoid tissue because no complemen-
tary TCR is present. Eventually, fpMHC is captured by an APC, which initiates 
2 independent processes. Firstly, the APC activates cytotoxic T cells to 
locate and eliminate the infection. The T cells travel via the blood vessel 
into the tissues. In the meantime the virus infects other cells in the body 
and is also released to the environment represented by small green dots. 
Secondly, the APC initiates hypermutation in B cells represented by 
coloured dots at the lower right part of the screen. Eventually, the green 
colour will appear as a new B cell clone and also become part of the 
extended immune defence filter.Bakács and Mehrishi BMC Cancer 2010, 10:251
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